AOLS - Aeolus Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Aeolus Pharmaceuticals, Inc.

26361 Crown Valley Parkway
Suite 150
Mission Viejo, CA 92691
United States
949-481-9825
http://www.aeoluspharma.com

SectorHealthcare
IndustryDrug Manufacturers - Other
Full Time Employees4

Key Executives

NameTitlePayExercisedAge
Mr. David C. CavalierChairman, CFO & Sec.374.02kN/A48
Mr. John L. McManusCEO & Pres460.33kN/A53
Mr. Christopher StanleyVP of OperationsN/AN/AN/A
Dr. Brian J. Day Ph.D.Chief Scientific OfficerN/AN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson’s disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Corporate Governance

Aeolus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.